While rare cases of idiosyncratic drug-induced liver injury have been reported, there is no established direct link between GLP-1 receptor agonists and serious hepatotoxicity in patients with normal baseline liver function
Glucagon-like peptide-1 (GLP-1) is an incretin hormone, produced by enteroendocrine cells (L cells) to regulate glucose and energy homeostasis via GLP-1R binding 16
Ferdousie VT, Mohammadi MM, Hassanshahi G, Khorramdelazad H, Falahati-Pour SK, Mirzaei M, Tavakoli MA, Kamiab Z, Ahmadi Z, Vazirinejad R, Shahrabadi E, Koniari I, Kounis NG, Esmaeili Nadimi A
Ideal timing for testing: Before starting your GLP-1 medication (baseline) 4-6 weeks after starting treatment After any dose increase Quarterly during stable dosing Immediately if warning symptoms appear People at higher risk for electrolyte problems include those over 65, anyone with kidney disease, heart failure patients, people taking diuretics, and anyone with persistent GI symptoms lasting beyond the first 8-12 weeks of treatment
In order to meet your individual needs, we customize our wellness services